Breakthrough T1D Advocates Have Been Hard at Work
Through these meetings, advocates give a voice to those impacted by T1D.
The CDC Updates its Guidelines to Prioritize T1D
On March 29, 2021, the U.S. Centers for Disease Control and Prevention (CDC) updated its guidelines to include type 1 diabetes (T1D) on the list of medical conditions associated with higher risk of becoming severely ill from COVID-19.
Special Diabetes Program (SDP) Renewed for Three Years!
One of Breakthrough T1D’s top legislative priorities has been achieved with the enactment of a three-year renewal of the Special Diabetes Program (SDP). The program, now funded until September 30, 2023 at $150 million per year, will enable researchers to build upon the momentum in type 1 diabetes (T1D) to date and explore new opportunities […]
Delay on Rule That Would Eliminate Medicare Part D Drug Rebates
On January 29, 2021, the Biden Administration delayed implementation of a recently adopted rule that would largely eliminate drug rebates in Medicare Part D. This rule had not yet been implemented and was scheduled to go into effect in 2022. This delay is part of the Biden Administration’s broader freeze on all regulations recently adopted […]
Department of Health & Human Services Freezes Rule Related to Insulin
As you may have heard from reports in the media the Biden Administration froze a recent regulation on insulin. Want to know what the headlines mean? Read on to get all the details. On January 21, the Biden Administration placed a freeze on all newly published regulations set forth by the previous Administration that had not yet been implemented. This includes a regulation that will require community health […]
Cass Freeland Builds Relationships with Political Power Players
NDAM Profile: Breakthrough T1D advocate Cass Freeland’s expertise in connecting with policy makers demonstrates The Power of Us.
Medicare Proposes Expanded Coverage of Continuous Glucose Monitors
The Centers for Medicare & Medicaid Services (CMS) proposed a new rule on October 27, 2020 that would expand coverage of important diabetes management devices. If finalized, this proposed regulation would expand Medicare coverage to all FDA-authorized continuous glucose monitors (CGMs) beginning on April 1, 2021. This proposed rule is welcomed by Breakthrough T1D as […]
Remember! Enroll in Medicare Part D plans that cap insulin costs at $35
This fall, it’s important to remember that open enrollment for health insurance is right around the corner. For those of you on Medicare, beginning October 15 through December 7, you can make critical changes to your health insurance to ensure you’re receiving the best coverage at the best price. For people with type 1 diabetes […]
FDA Approves an Artificial Pancreas System for Children Aged 2-6 Years
The Food and Drug Administration (FDA) approved the Medtronic MiniMed 770G artificial pancreas system for use by children aged 2 to 6 with type 1 diabetes (T1D). It is the first marketed device that can automatically adjust insulin delivery based on continuous glucose monitoring (CGM) values for children aged 2-6 years.
Executive Orders on Drug Pricing
On July 24, the White House released three Executive Orders related to drug pricing.
